A Study on the Mechanism of Action of Galangal in the Treatment of Gastric Cancer Using Network Pharmacology Technology
Abstract
:1. Introduction
2. Materials and Methods
2.1. Mining and Screening of Effective Compounds and Their Targets in Galangal
2.2. Screening Genes Related to Gastric Cancer
2.3. Construction of “Compound-Interactive Gene” Network of Galangal
3. Results
3.1. Basic Information of Effective Compounds in Galangal
3.2. Venn Analysis of Effective Compound Targets of Galangal and Target Genes of Gastric Cancer
3.3. Galangal-Component-Target-Gastric Cancer Network Construction
3.4. PPI Network Construction
3.5. GO Enrichment Analysis Results
3.6. KEGG Enrichment Analysis
3.7. Molecular Docking
4. Discuss
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Liu, Z.; Li, Z.; Zhang, Y.; Zhou, T.; Zhang, J.; You, W.; Pan, K.; Li, W. Interpretation of the 2020 Global Cancer Statistical Report. Electron. J. Compr. Cancer Ther. 2021, 7, 1–14. [Google Scholar]
- Jiangsu New Medical College (Ed.) Dictionary of Traditional Chinese Medicine; Shanghai People’s Publishing House: Shanghai, China, 1977. [Google Scholar]
- Liu, W.; Yu, P. Antitumor mechanism of traditional Chinese medicine flavonoids. J. Chang. Univ. Tradit. Chin. Med. 2015, 31, 254–255. [Google Scholar]
- Weiru, R.; Depo, Y.; Lin, Y.; Dongmei, W.; Feng, H.; Changsheng, C.; Li, G. Analysis of chemical constituents of 1,8-eucalyptol and volatile oil in different parts of galangal. Nat. Prod. Res. Dev. 2007, 19, 389–392. [Google Scholar]
- Lu, W.; Jiang, L. Chemical constituents and pharmacological effects of galangal. China Pharm. 2006, 15, 19–21. [Google Scholar]
- Liu, X.; Zhang, Z.; Duan, Y.; Qianguang, L.; Jun, C. Antioxidative effect of commercially available natural plant flavors. Food Sci. 2002, 23, 143–145. [Google Scholar]
- Akhtar, M.S.; Khan, M.A.; Malik, M.T. Hypoglycaemic activity of Alpinia galanga rhizome and its extracts in rabbits. Fitoterapia 2002, 73, 623–628. [Google Scholar] [CrossRef]
- Felice, S.; Francesca, L.; Francesca, V.; Maurizio, B.; Francesco, N. Composition and antibacterial activity of the essential oil of Anisochilus carnosus (Linn.fil.) Benth. a Tamil plant acclimatized in Sicily. Flavour Fragr. J. 2003, 18, 202–204. [Google Scholar]
- Wu, Q.; Caodian Group; Huang, P.; Xiang, L. Effects of galangal supercritical extract on ulcer formation and levels of epidermal growth factor and interleukin-2 in stress ulcer rats. Chin. Med. Pharmacol. Clin. 2004, 20, 17–18. [Google Scholar]
- Hui, L.; Chao, M.; Yajun, W.; Chen, J.; Liu, J.-Q.; Zhang, H.-T. Study on the apoptosis of liver cancer BEL-7402 cells induced by galangin. Chin. Mater. Med. 2008, 31, 1024–1027. [Google Scholar]
- Yanagisawa, H.; Miyashita, T.; Nakano, Y.; Yamamoto, D. HSpin1, a transmembrane protein interacting with Bcl-2/BclxL, induces a caspase-independent autophagic cell death. Cell Death Differ. 2003, 10, 798–807. [Google Scholar] [CrossRef] [Green Version]
- Zhang, W.; Tang, B.; Huang, Q.; Hua, Z. Galangin inhibits tumor growth and metastasis of B16F10 melanoma. J. Cell. Biochem. 2013, 114, 152–161. [Google Scholar] [CrossRef] [PubMed]
- Rozi, B.L.; Amat, M.; Rally, E.M.; Meatzi, N.; Abdullah, A. Effects of galangin on apoptosis and gene expression of cervical cancer SiHa cells. J. Xinjiang Med. Univ. 2016, 39, 1595–1600. [Google Scholar]
- Xu, Y.; Zhao, X. In vitro effects of galangin on the proliferation, cycle and apoptosis of human gastric cancer SGC-7901 cells. Chin. J. Pharm. 2013, 48, 1274–1278. [Google Scholar]
- Liu, Z.; Wang, H. The apoptosis effect of galangin on liver cancer cells HepG-2. Food Ind. Sci. Technol. 2020, 41, 299–304. [Google Scholar]
- W -W, Z.; S -P, X. Galangin inhibits the cell progression and induces cell apoptosis through activating PTEN and Caspase-3 pathways in retinoblastoma. Biomed. Pharmacother. 2018, 97, 851–863. [Google Scholar]
- Liang, X.; Yu, M.; Shi, H.; Wu, X. Galangin inhibits NF-κB pathway in gastric cancer MGC803 cells and promotes autophagy. China J. Tradit. Chin. Med. 2021, 46, 4167–4174. [Google Scholar]
- Luo, Y.; Liu, D. Galangin on Inhibitory effect of different tumor cells. Jilin Tradit. Chin. Med. 2021, 40, 948–950. [Google Scholar]
- Ma, L.; Tian, G.; Geng, H.; Wang, Y.; Zhang, Y.; Ma, M.; Lü, J. Introduction to TCMSP and its analysis and application in the systemic pharmacology database of traditional Chinese medicine. Chin. J. Evid. Based Cardiovasc. Med. 2020, 12, 1413–1416. [Google Scholar]
- Yang, M.; Du, J.; Li, D.; Yang, Q.; Liu, W.; Yao, H. Construction and research of miRNA regulatory network based on Cytoscape. China Med. Equip. 2018, 15, 95–97. [Google Scholar]
- Haohua, T.G.; Geng, H.; Wang, Y.; Zhang, Y.; Ma, M.; Lü, J. Introduction to the application of the GeneCards database for comprehensive analysis of human genes. Chin. J. Evid. Based Cardiovasc. Med. 2021, 13, 902–906. [Google Scholar]
- Smyth, E.C.; Nilsson, M.; Grabsch, H.I.; van Grieken, N.C.T.; Lordick, F. Gastric cancer. Lancet 2020, 1025, 2654–2664. [Google Scholar] [CrossRef]
- Wang, J. Surgery for Gastric Cancer; People’s Health Publishing House: Beijing, China, 2000; p. 395. [Google Scholar]
- Zhang, Z. Clinical observation of 30 cases of advanced gastric cancer treated with integrated traditional Chinese and Western medicine. China Mod. Drug Appl. 2012, 6, 58–59. [Google Scholar]
- Yin, Z.; Liu, G.; Li, X.; Bai, Y.; Qi, W.; Liu, L.; Chen, H. Research progress on targeted therapy drugs and drug resistance mechanisms for gastric cancer. China Oncol. 2021, 30, 701–710. [Google Scholar]
- Feng, F.; Lv, J.; Ran, S. Research progress in the treatment of gastric cancer with integrated traditional Chinese and Western medicine. Pop. Sci. Technol. 2018, 20, 74–76. [Google Scholar]
- State Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China; China Pharmaceutical Science and Technology Press: Beijing, China, 2015. [Google Scholar]
- Qin, H.; Liu, L.; Wang, X. Research progress on volatile oil constituents of Alpinia spp. Res. Dev. Nat. Prod. 2012, 24, 190–192+82. [Google Scholar]
- Bu, X.; Xiao, G.; Gu, L.; Zhang, M. Study on the chemical constituents of Galangal. Chin. Mater. Med. 2000, 23, 84–87. [Google Scholar]
- Li, C.; Chen, Y.; He, R. Research Progress on Diphenylheptane Compounds in Galangal. Shizhen Tradit. Chin. Med. 2000, 4, 367–368. [Google Scholar]
- Yu, M.; Ouyang, J.; Feng, W.; Xiong, L.; Chen, Y. Modern research progress on antibacterial effects of galangal. Mod. Chin. Med. Res. Pract. 2019, 33, 82–86. [Google Scholar]
- Lee, S.E.; Huang, H.J.; Ha, J.S.; Jeong, H.-S.; Kim, J.H. Screening of medicinal plant extracts for antioxidant activity. Life Sci. 2003, 73, 167–179. [Google Scholar] [CrossRef]
- Li, M.; Tan, Y. Hypoglycemic effect of galangal extract on type 2 diabetic mice. Hainan Med. 2016, 27, 864–867. [Google Scholar]
- Kim, D.A.; Jeon, Y.K.; Nam, M.J. Galangin induces apoptosis in gastric cancer cells via regulation of ubiquitin carboxy-terminal hydrolase isozyme L1 and glutathione S-transferase P. Food Chem. Toxicol. 2012, 50, 684–688. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Jiang, T.; Tang, C.; Feng, Y.; Yang, C. Experimental study on anti-inflammatory and analgesic effects of total flavonoids of galangal. J. Guangdong Univ. Pharm. 2009, 25, 188–191. [Google Scholar]
- Gao, L.; Li, X.; Zhang, X.; Wang, J. Research progress on the mechanism of action of quercetin in hepatocellular carcinoma. J. Chifeng Univ. 2021, 37, 65–70. [Google Scholar]
- Zhu, S.; Lu, L.; Bi, L.; Qin, F.; Li, J. Quercetin affects the proliferation of gastric cancer cells and induces apoptosis. Straits Pharm. 2021, 33, 14–17. [Google Scholar]
- Song, H.B.; Bao, J.J.; Wei, Y.Z.; Chen, Y.; Mao, X.; Li, J.; Yang, Z.; Xue, Y. Kaempferol inhibits gastric cancer tumor growth: An in vitro and in vivo study. Oncol. Rep. 2015, 33, 868–874. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jing, Z.; Shi, X.; Wei, M.E.N.G.; Ma, F.; Zhao, L.; Zhao, F. Kaempferol inhibits the invasion and migration of A549 cells in non-small cell lung cancer by down-regulating ERRα. Chin. J. Oncol. Biother. 2018, 25, 1230–1236. [Google Scholar]
- Jing, R.; Dai, Q.; Chen, R.; Guan, C.; Liu, W.; Li, X. Research progress on the anti-cancer effect and mechanism of isopurine lithrin. China Med. Her. 2022, 19, 37–41. [Google Scholar]
- Seo, S.; Seo, K.; Ki, S.H.; Sang, M.S. Isorhamnetin Inhibits Reactive Oxygen Species-Dependent Hypoxia Inducible Factor(HIF)-1α Accumulation. Biol. Pharm. Bull. 2016, 39, 1830–1838. [Google Scholar] [CrossRef] [Green Version]
- Cheng, J.; Liu, J.; Chen, F.; Lü, X.; Fei, S.; Yang, Y. The effect of β-sitosterol on human natural killer cells killing PANcreatic cancer SW-1990 cells. Lab. Med. Clin. 2012, 9, 3078–3082. [Google Scholar]
- Chen, Z.; Zhang, J.; Yang, X.; Lv, H.; Carter, V.W. New advances in the research of tumor suppressor genes TP53 and new family members TP63 and TP73. J. Inn. Mong. Med. Univ. 2013, 35, 57–62. [Google Scholar] [CrossRef]
- Li, X.; Kong, X.; Wang, Y.; Yang, Q. BRCC2 inhibits breast cancer cell growth and metastasis in vitro and in vivo via downregulating AKT pathway. Cell Death Dis. 2013, 4, e757. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, Z.; Jia, X.; Xu, Q.; Chen, F.; Peng, F.; Ban, N.; Zhang, Z. The Relationship between AKT1 and STMN1 Expression in Gastric Cancer Tissues and Its Clinical Significance. Tumor Basics Clin. 2019, 32, 471–474. [Google Scholar]
- Liang, X.; Zhang, J.; Bai, H.; Li, Y.; Sun, S.; Zhang, Q.; Yang, J.; Wang, R. Discussion on the Mechanism of Action of Wu Yao Against Gastric Cancer Based on Network Pharmacology and In Vitro Experimental Verification. Chin. J. Chin. Mater. Med. 2022, 47, R285.5. [Google Scholar] [CrossRef]
- Lin, S.; Qin, H.; Li, Z.; Liba, L.; Deng, L.; Luo, J.; Xie, F.; Zhang, M.; Zhu, H.; Wang, X. Effects of total alkaloids on apoptosis of A549 cells in human lung cancer and PI3K/Akt and JNK/p38 MAPK signaling pathways[J/OL]. Chin. J. Exp. Formul. 2022, 14, 57. [Google Scholar] [CrossRef]
- Rose, B.A.; Force, T.; Wang, Y. Mitogen-activated protein kinase signaling in the heart:angels versus demons in a heart-breaking tale. Physiol. Rev. 2010, 90, 1507–1546. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, J.; Shao, L.; Chen, D. Research Progress on Heterozygous Antimicrobials. Chin. J. Pharm. Ind. 2017, 48, 1233–1246. [Google Scholar]
Mol ID | Molecule Name | OB (%) | DL |
---|---|---|---|
MOL001771 | poriferast-5-en-3beta-ol | 36.91 | 0.75 |
MOL002543 | (2S,3R)-2-(3,4-dimethoxyphenyl)-5,7-dimethoxychroman-3-ol | 51.89 | 0.37 |
MOL002544 | 1,7-diphenyl-5-hydroxy-3-heptanone | 61.9 | 0.18 |
MOL002554 | 5-methoxy-1,7-diphenyl-3-heptanone | 68.29 | 0.2 |
MOL002556 | 7-Methoxy-8-(2’-ethoxy-3’-hydroxy-3’-methybutyl)coumarin | 40.36 | 0.21 |
MOL002563 | galangin | 45.55 | 0.21 |
MOL002565 | Medicarpin | 49.22 | 0.34 |
MOL002575 | butyl-2-ethylhexyl phthalate | 44.52 | 0.22 |
MOL000354 | isorhamnetin | 49.6 | 0.31 |
MOL000358 | beta-sitosterol | 36.91 | 0.75 |
MOL000359 | sitosterol | 36.91 | 0.75 |
MOL000422 | kaempferol | 41.88 | 0.24 |
MOL000098 | quercetin | 46.43 | 0.28 |
Classification | Pathway | Count | % | Log10 (p) | Log10 (q) |
---|---|---|---|---|---|
TOP10 MF | GO:0140297:DNA-binding transcription factor binding | 30 | 20 | −23.91 | −20.22 |
GO:0019900:kinase binding | 31 | 20.67 | −19.09 | −16 | |
GO:0004879:nuclear receptor activity | 13 | 8.67 | −18.45 | −15.56 | |
GO:0019904:protein domain specific binding | 28 | 18.67 | −17.1 | −14.32 | |
GO:0042803:protein homodimerization activity | 27 | 18 | −16.2 | −13.47 | |
GO:0004672:protein kinase activity | 24 | 16 | −15.06 | −12.42 | |
GO:0044389:ubiquitin-like protein ligase binding | 18 | 12 | −13.47 | −10.94 | |
GO:0005126:cytokine receptor binding | 17 | 11.33 | −13.45 | −10.94 | |
GO:0019207:kinase regulator activity | 16 | 10.67 | −13.23 | −10.75 | |
GO:0020037:heme binding | 11 | 7.33 | −9.95 | −7.74 | |
TOP10 BP | GO:0009725:response to hormone | 52 | 34.67 | −44.57 | −40.67 |
GO:0071396:cellular response to lipid | 46 | 30.67 | −44.56 | −40.67 | |
GO:0010035:response to inorganic substance | 44 | 29.33 | −41.13 | −37.54 | |
GO:0009410:response to xenobiotic stimulus | 39 | 26 | −38.39 | −34.98 | |
GO:0032496:response to lipopolysaccharide | 35 | 23.33 | −36.24 | −32.95 | |
GO:0009991:response to extracellular stimulus | 35 | 23.33 | −30.27 | −27.26 | |
GO:0009314:response to radiation | 34 | 22.67 | −30.22 | −27.23 | |
GO:0070482:response to oxygen levels | 30 | 20 | −29.29 | −26.36 | |
GO:0051272:positive regulation of cellular component movement | 37 | 24.67 | −29.19 | −26.28 | |
GO:0048545:response to steroid hormone | 28 | 18.67 | −28.03 | −25.21 | |
TOP10 CC | GO:0045121:membrane raft | 20 | 13.33 | −15.58 | −12.68 |
GO:0005667:transcription regulator complex | 23 | 15.33 | −15.49 | −12.68 | |
GO:1902911:protein kinase complex | 12 | 8 | −12.24 | −9.56 | |
GO:0031983:vesicle lumen | 14 | 9.33 | −8.96 | −6.52 | |
GO:0031012:extracellular matrix | 16 | 10.67 | −7.57 | −5.42 | |
GO:0098797:plasma membrane protein complex | 17 | 11.33 | −7.05 | −4.94 | |
GO:1905286:serine-type peptidase complex | 4 | 2.67 | −6.73 | −4.67 | |
GO:0097180:serine protease inhibitor complex | 3 | 2 | −5.62 | −3.62 | |
GO:0048471:perinuclear region of cytoplasm | 15 | 10 | −5.49 | −3.55 | |
GO:0005819:spindle | 11 | 7.33 | −5.24 | −3.33 |
KEGG Signaling Pathway | Count | % | Log10 (p) | Log10 (q) |
---|---|---|---|---|
hsa05200:Pathways in cancer | 67 | 44.67 | −76.4 | −73.86 |
hsa05417:Lipid and atherosclerosis | 42 | 28 | −54.83 | −52.6 |
hsa04933:AGE-RAGE signaling pathway in diabetic complications | 32 | 21.33 | −49.23 | −47.17 |
hsa05161:Hepatitis B | 33 | 22 | −43.44 | −41.6 |
hsa05207:Chemical carcinogenesis-receptor activation | 34 | 22.67 | −40.97 | −39.21 |
hsa04010:MAPK signaling pathway | 27 | 18 | −25.67 | −24.61 |
hsa05205:Proteoglycans in cancer | 24 | 16 | −25.37 | −24.33 |
hsa01524:Platinum drug resistance | 17 | 11.33 | −23.43 | −22.48 |
hsa04068:FoxO signaling pathway | 18 | 12 | −20.36 | −19.53 |
hsa05202:Transcriptional misregulation in cancer | 20 | 13.33 | −20.13 | −19.31 |
hsa04064:NF-kappa B signaling pathway | 16 | 10.67 | −18.96 | −18.19 |
hsa04915:Estrogen signaling pathway | 17 | 11.33 | −18.41 | −17.67 |
hsa05323:Rheumatoid arthritis | 14 | 9.33 | −16.5 | −15.82 |
hsa04919:Thyroid hormone signaling pathway | 15 | 10 | −16.34 | −15.66 |
hsa05144:Malaria | 11 | 7.33 | −15.01 | −14.36 |
hsa05221:Acute myeloid leukemia | 11 | 7.33 | −13.5 | −12.88 |
hsa04630:JAK-STAT signaling pathway | 14 | 9.33 | −13.06 | −12.47 |
hsa04370:VEGF signaling pathway | 10 | 6.67 | −12.46 | −11.9 |
hsa04914:Progesterone-mediated oocyte maturation | 11 | 7.33 | −11.42 | −10.88 |
hsa04020:Calcium signaling pathway | 14 | 9.33 | −10.73 | −10.2 |
Target | Active Ingredient | Bindin Genergy /kcal·mol−1 |
---|---|---|
TP53 | quercetin | −6.4 |
kaempferol | −6.4 | |
JUN | quercetin | −4.6 |
kaempferol | −4.7 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tao, A.; Feng, X.; Song, Z.; Xu, R.; Zhao, Y. A Study on the Mechanism of Action of Galangal in the Treatment of Gastric Cancer Using Network Pharmacology Technology. Processes 2022, 10, 1988. https://doi.org/10.3390/pr10101988
Tao A, Feng X, Song Z, Xu R, Zhao Y. A Study on the Mechanism of Action of Galangal in the Treatment of Gastric Cancer Using Network Pharmacology Technology. Processes. 2022; 10(10):1988. https://doi.org/10.3390/pr10101988
Chicago/Turabian StyleTao, Ali, Xuehua Feng, Zurong Song, Rui Xu, and Ying Zhao. 2022. "A Study on the Mechanism of Action of Galangal in the Treatment of Gastric Cancer Using Network Pharmacology Technology" Processes 10, no. 10: 1988. https://doi.org/10.3390/pr10101988